NCT02484911View on ClinicalTrials.gov

Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

September 30, 2016

Study Completion Date

January 31, 2017

Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
DRUG

Olanzapine

5mg,twice a day orally on day 1 to day 4

DRUG

Aprepitant

125 mg capsule per oral, 1 hour before chemotherapy on day 1, 80 mg capsule daily in the morning during days 2 to 3.

DRUG

Palonosetron

0.25mg IV 30-60min before chemotherapy on day 1

DRUG

Dexamethasone

6mg IV on day 1 ，3.75mg IV on day 2 to 4

Trial Locations (1)

150000

First Affiliated Hospital of Harbin Medical University, Harbin

All Listed Sponsors
collaborator

Harbin Medical University

OTHER

lead

First Affiliated Hospital of Harbin Medical University

OTHER

NCT02484911 - Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting | Biotech Hunter | Biotech Hunter